GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Implantica AG (OSTO:IMP A SDB) » Definitions » 3-Year Dividend Growth Rate

Implantica AG (OSTO:IMP A SDB) 3-Year Dividend Growth Rate : 0.00% (As of . 20)


View and export this data going back to 2020. Start your Free Trial

What is Implantica AG 3-Year Dividend Growth Rate?

Implantica AG's Dividends per Share for the six months ended in . 20 was kr0.00.

The historical rank and industry rank for Implantica AG's 3-Year Dividend Growth Rate or its related term are showing as below:

OSTO:IMP A SDB's 3-Year Dividend Growth Rate is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 7.7
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Implantica AG's Dividend Payout Ratio for the six months ended in . 20 was 0.00. As of today, Implantica AG's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of Implantica AG's 3-Year Dividend Growth Rate

For the Medical Devices subindustry, Implantica AG's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Implantica AG's 3-Year Dividend Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Implantica AG's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Implantica AG's 3-Year Dividend Growth Rate falls into.


;
;

Implantica AG 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.


Implantica AG  (OSTO:IMP A SDB) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Implantica AG's Dividend Payout Ratio for the quarter that ended in . 20 is calculated as

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Implantica AG 3-Year Dividend Growth Rate Related Terms>


Implantica AG Business Description

Comparable Companies
Traded in Other Exchanges
Address
Aeulestrasse 45, Vaduz, LIE, 9490
Implantica AG is a medtech group providing effective care for serious health conditions and improving patients' quality of life by bringing advanced technology into the body. The therapies Implantica develops are based on implants that are medical devices inserted into the patient's body and are intended to remain in place permanently or semi-permanently, using electrical power provided by a battery. The company has developed a broad, patent-protected, product pipeline based partly on its two platform technologies. Its lead product, RefluxStop, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results.

Implantica AG Headlines

No Headlines